Bend Bioscience, a science, and pharmaceutical services partner, announced the addition of a commercial-scale spray dryer and a Gerteis dry granulation system at its 120,000-square-foot facility in Gainesville, Georgia. 

The Gainesville facility specializes in oral solid dosage forms and is a center of excellence for commercial manufacturing, modified release, and multiparticulates. 

The new equipment is being shipped to the Gainesville facility this month and the installation process will begin immediately to align with potential customer timelines.

GEA PSD-4, the new spray drying suite will include adjacent secondary vacuum drying systems, multiple tank sizes to accommodate flexible campaigns and batch sizes, a dual-stage condenser capable of handling a wide range of process solvents, and the ability to process potent APIs. 

This new equipment will expand the Gainesville facility’s capabilities to provide technologically advanced absorption and bioavailability-enhanced products, and clinical and commercial scale oral dose forms.

Owen Murray, CEO of Bend Bioscience said, “This expansion not only reinforces our position as a leader in the pharmaceutical services industry, but also allows us to meet the demands of significant near-term growth through our network of capabilities and expertise in enhancing pharmacokinetics, particle engineering and modified release forms.”

These new capabilities complement the company’s clinical development expertise in spray-dried dispersions at its site in Bend, Oregon, and strengthen Bend Bioscience’s ability to support existing and new early-phase customers.